Retrospective Evaluation of the Analgesic Effects of Molecular Target Agents Against Cancer Pain and Oxaliplatin-Induced Chronic Peripheral Neuropathy
DOI:
https://doi.org/10.30683/1927-7229.2022.11.06Keywords:
EGFR, Panitumumab, cancer pain, nociceptive pain, chronic chemical induced peripheral neuropathyAbstract
Epidermal growth factor receptor (EGFR) has received significant attention for its therapeutic potential for pain relief. The relief of neuropathic pain after treatment with anti-EGFR antibodies or tyrosine kinase inhibitors has been previously described. However, few reports have investigated the association of cancer-related nociceptive pain or chronic chemical induced peripheral neuropathy with the analgesic effects of EGFR inhibition.
Therefore, we conducted a retrospective survey of 191 patients with colorectal cancer receiving chemotherapy plus molecular targeting drugs to examine the analgesic effects of anti-EGFR antibodies against either cancer pain or oxaliplatin-induced peripheral neuropathy. We identified a significant difference in the improvement rates of nociceptive pain between panitumumab- and bevacizumab-treated patients (100% vs. 9.1%; p < 0.01), but not oxaliplatin-induced peripheral neuropathy.
In conclusion, panitumumab may be effective at reducing cancer-related nociceptive pain.
References
Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10. https://doi.org/10.1038/35093019
Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and EGFR interactions are involved in pain processing. J Clin Invest 2017; 127: 3353-66. https://doi.org/10.1172/JCI87406
Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013; 8: 229-37. https://doi.org/10.1097/JTO.0b013e3182773fce
Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain. Br J Anaesthesia 2015; 115: 761-767. https://doi.org/10.1093/bja/aev326
Kersten C, Cameron MG, Bailey AG, et al. Relief of neuropathic pain through epidermal growth factor receptor inhibition: A randomized proof-of-concept trial. Pain Med 2019; 20: 2495-2505. https://doi.org/10.1093/pm/pnz101
Kersten C, Cameronb MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Reports 2012. pii: bcr1220115374. https://doi.org/10.1136/bcr.12.2011.5374
Yuasa S, Kabeya M, Furuta R, et al. Case of sigmoid colon cancer in which somatic pain was rapidly alleviated after panitumumab administration despite tumor progression. J Anal Oncol 2016; 5: 38-41. https://doi.org/10.6000/1927-7229.2016.05.01.5
Borges JP, Mekhail K, Fairn GD, Antonescu CN, Steinberg BE. Modulation of pathological pain by epidermal growth factor receptor. Front Pharmacol 2021; 12: 642820. https://doi.org/10.3389/fphar.2021.642820
Zhuang ZY, Gerner P, Woolf C, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005; 114: 149-59. https://doi.org/10.1016/j.pain.2004.12.022
Douillard JY, Siena S, Cassidy J, et al. Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010; 28: 4697-705. https://doi.org/10.1200/JCO.2009.27.4860
Kang L, Tian Y, Xu S, Chen H. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol 2021; 268: 3269-82. https://doi.org/10.1007/s00415-020-09942-w
Japanese society for palliative medicine. Clinical guideline for cancer pain management third edition, Kanehara & Co. Ltd, Tokyo Japan 2020; pp. 22-26.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation 2013; 48: 452-458. https://doi.org/10.1038/bmt.2012.244
Puig S, Donica CL, Gustein HB. EGFR signaling causes morphine tolerance and mechanical sensitization in rats. eNeuro 2020; 7: 1-12. https://doi.org/10.1523/ENEURO.0460-18.2020
Verma V, Khoury S, Parisien M, et al. The dichomatous role of epiregulin in pain. Pain 2020; 161: 1052-64. https://doi.org/10.1097/j.pain.0000000000001792
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.